JGC
IOVA icon

J. Goldman & Co’s Iovance Biotherapeutics IOVA Stock Holding History

J. Goldman & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,000
Closed -$400K – 520
2024
Q1 		$400K Buy
+27,000
New +$314K 0.01% 336
2023
Q4 		– Sell
-54,000
Closed -$246K – 407
2023
Q3 		$246K Buy
+54,000
New +$353K 0.01% 308
2023
Q2 		– Sell
-405,000
Closed -$2.47M – 436
2023
Q1 		$2.47M Buy
+405,000
New +$2.79M 0.1% 196
2021
Q1 		– Sell
-18,000
Closed -$835K – 480
2020
Q4 		$835K Buy
+18,000
New +$715K 0.04% 251
2020
Q2 		– Sell
-50,000
Closed -$1.5M – 301
2020
Q1 		$1.5M Buy
+50,000
New +$1.33M 0.18% 122

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

J. Goldman & Co's IOVA Position: Q4 2023 in Review

J. Goldman & Co sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 13,500 shares — an estimated $61.4K sold.

J. Goldman & Co first reported a position in IOVA in Q1 2020 and held it in 3 quarters. The position peaked at $3.98M in Q1 2023. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • J. Goldman & Co reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Iovance Biotherapeutics shares in Q4 2023, an estimated $61.4K.
  • J. Goldman & Co first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 3 quarters.
  • J. Goldman & Co's Iovance Biotherapeutics position peaked at $3.98M in Q1 2023.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.